注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Celcuity Inc是一家臨床階段生物技術公司。該公司正在尋求通過實施綜合治療(Rx)和伴隨診斷(CDx)策略來延長癌症患者的生命。它的治療工作集中在開發分子靶向治療,以解決CELsignia同伴診斷可以識別的相同癌症驅動因素。該公司的主要候選治療藥物是gedatolisib,一種有效、可逆的雙抑製劑,選擇性靶向PI3K的所有I類亞型和雷帕黴素(mTOR)的哺乳動物靶向。其作用機制和藥代動力學特性與單獨或聯合靶向PI3K或mTOR的其他研究治療有很大區別。 Gedatolisib最初的臨床開發計劃側重於激素受體陽性(HR+)、HER2陰性、晚期或轉移性乳腺癌患者的治療。該公司的其他臨床開發計劃側重於各種其他腫瘤類型。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Mothaffar F. Rimawi | - | 2019 | Member of Scientific Advisory Board |
Lee S. Schwartzberg | - | 2019 | Member of Scientific Advisory Board |
Richard E. Buller | 71 | 2019 | Independent Director |
Manfred Auer | - | - | Member of Scientific Advisory Board |
Mark D. Pegram | - | - | Member of Scientific Advisory Board |
Stanley M. Marks | 74 | - | Member of Scientific Advisory Board |
Adam M. Brufsky | - | - | Member of Scientific Advisory Board |
Lance G. Laing | 59 | 2012 | Co-Founder, Chief Science Officer, VP, Secretary & Director |
Brian F. Sullivan | 59 | 2012 | Co-Founder, Chairman & CEO |
Edward Greeno | - | - | Member of Scientific Advisory Board |
Richard J. Nigon | 74 | 2017 | Independent Director |
Carol Lange | - | - | Member of Scientific Advisory Board |
Ronald C. McGlennen | - | - | Member of Scientific Advisory Board |
Benita Katzenellenbogen | - | - | Member of Scientific Advisory Board |
Sara Hurvitz | - | - | Member of Scientific Advisory Board |
David F. Dalvey | 64 | 2014 | Independent Director |
John Katzenellengogen | - | - | Member of Scientific Advisory Board |
Leo T. Furcht | 75 | 2019 | Independent Director |
Ben Ho Park | - | 2020 | Member of Scientific Advisory Board |
Bora Lim | - | 2020 | Member of Scientific Advisory Board |
Hung Khong | - | 2021 | Member of Scientific Advisory Board |
Alberto Montero | - | 2021 | Member of Scientific Advisory Board |
Polly A. Murphy | 58 | 2022 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核